1. Almkvist O, Wahlund L-O, Andersson-Lundman G, Basun H, Bäckman L. White-matter hyperintensity and neuropsychological functions in dementia and healthy aging. Arch Neurol 1992;49:626–632.

2. Azari NP, Pettigrew KD, Schapiro MB, et al. Early detection of Alzheimer's disease: a statistical approach using positron emission tomographic data. J Cereb Blood Flow Metab 1993;13:438–447.

3. Benson DF, Kuhl DE, Hawkins RA, Phelps ME, Cummings JL, Tsai SY. The fluorodeoxyglucose 18F scan in Alzheimer's disease and multi-infarct dementia. Arch Neurol 1983;40:711–714.

4. Boller F, Lopez OL, Moossy J. Diagnosis of dementia: clinicopathologic correlations. Neurology 1989;39:76–79.

5. Bowen BC, Barker WW, Loewenstein DA, Sheldon J, Duara R. MR signal abnormalities in memory disorder and dementia. AJR 1990;154:1285–1292.

6. Brown GG, Levine SR, Gorell JM, et al. In vivo 31P NMR profiles of Alzheimer's disease and multiple subcortical infarct dementia. Neurology 1989;39:1423–1427.

7. Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's disease diagnostic and treatment centers. Neurology 1992;42:473–480.

8. Claus JJ, Hasan D, van Harskamp FH, et al. SPECT with 99mTc-HMPAO is of limited diagnostic value in mild Alzheimer's disease: a population-based study. Neurology 1993;43(Suppl 2):A406.

9. Creasey H, Schwartz M, Frederickson H, Haxby JV, Rapoport SI. Quantitative computed tomography in dementia of the Alzheimer type. Neurology 1986;36:1563–1568.

10. DeCarli C, Grady CL, Clark CM, et al. Leukoencephalopathy in dementia of the Alzheimer type. Submitted for publication.

11. DeCarli C, Haxby JV, Gillette JA, Teichberg D, Rapoport SI, Schapiro MB. Longitudinal changes in lateral ventricular volume in patients with dementia of the Alzheimer type. Neurology 1992;42:2029–2036.

12. DeCarli C, Kaye JA, Horwitz B, Rapoport SI. Critical analysis of the use of computer-assisted transverse axial tomography to study human brain in aging and dementia of the Alzheimer type. Neurology 1990;40:872–883.

13. DeCarli C, Murphy DGM, McIntosh AR, Teichberg D, Schapiro MB, Horwitz B. Discriminate analysis of MRI measures determines the presence of dementia of the Alzheimer type in males and females. [Submitted.]

14. DeCarli CS, Atack JR, Ball MJ, et al. Post-mortem regional neurofibrillary tangle densities but not senile plaque densities are related to regional cerebral metabolic rates for glucose during life in Alzheimer's disease patients. Neurodegeneration 1992;1:113–121.

15. DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol 1990;27:457–464.

16. Spitzer RL, ed. Diagnostic and statistical manual of mental disorders, 3rd ed. (revised) (DSM-III-R). Washington, DC: American Psychiatric Association, 1987;567.

17. Drayer BP. Imaging of the aging brain. Part II. Pathologic conditions. Radiology 1988;166:797–806.

18. Duara R, Barker WW, Chang J, Yoshii F, Loewenstein DA, Pascal S. Viability of neocortical function shown in behavioral activation state PET studies in Alzheimer disease. J Cereb Blood Flow Metab 1992;12:927–934.

19. Duara R, Grady C, Haxby J, et al. Positron emission tomography in Alzheimer's disease. Neurology 1986;36:879–887.

20. Folstein MF, Folstein SE, McHugh PR. "Mini Mental State"—a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.

21. Fox PT, Raichle ME, Mintun MA, Dence C. Nonoxidative glucose consumption during focal physiologic neural activity. Science 1988;241:462–464.

22. Frackowiak RSJ, Pozzilli C, Legg NJ, Du Boulay GH, Marshall J, Lenzi GL, Jones T. Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography. Brain 1981;104:753–778.

23. Friedland RP, Jagust WJ, Huesman RH. Regional cerebral glucose transport and utilization in Alzheimer's disease. Neurology 1989; 39:1427–1434.

24. Gado M, Hugh CP, Danziger W, Chi D. Aging, dementia, and brain atrophy: a longitudinal computed tomographic study. AJNR 1983;4:699–702.

25. Geaney DP, Soper N, Shepstone BJ, Cowen PJ. Effect of central cholinergic stimulation on regional cerebral blood flow in Alzheimer's disease. Lancet 1990;335:1484–1487.

26. Grady CL, Haxby JV, Horwitz B, et al. Activation of cerebral blood flow during a visuoperceptual task in patients with Alzheimer-type dementia. Neurobiol Aging 1993;14:35–44.

27. Grady CL, Haxby JV, Horwitz B, et al. Longitudinal study of the early neuropsychological and cerebral metabolic changes in dementia of the Alzheimer type. J Clin Exp Neuropsychol 1988;10:576–596.

28. Grady CL, Haxby JV, Schapiro MB, et al. Subgroups in dementia of the Alzheimer type identified using positron emission tomography. J Neuropsychol Clin Neurosci 1990;2:373–384.

29. Hachinski V. Preventable senility: a call for action against the vascular dementias. Lancet 1992;340:645–648.

30. Hagberg BO, Ingvar DH. Cognitive reduction in presenile dementia related to regional abnormalities of cerebral blood flow. Br J Psychiatry 1976;128:209–222.

31. Haxby JV, Grady CL, Koss E, et al. Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Arch Neurol 1990;47:753–760.

32. Haxby JV, Grady CL, Koss E, Horwitz B, Schapiro M, Friedland RP, Rapoport SI. Heterogeneous anterior–posterior metabolic patterns in dementia of the Alzheimer type. Neurology 1988;38:1853–1863.

33. Haxby JV, Raffaele K, Gillette J, Schapiro MB, Rapoport SI. Individual trajectories of cognitive decline in patients with dementia of the Alzheimer type. J Clin Exp Neuropsychol 1992;14:575–592.

34. Heiss W-D, Kessler J, Slansky I, Mielke R, Szelies B, Herholz K. Metabolic activation by a visual recognition task for assessment of therapeutic efficacy in Alzheimer's disease. Ann Nucl Med [Suppl] 1993;7:S124–S125.

35. Hoffman JM, Guze BH, Baxter L, et al. Metabolic homogeneity in familial and sporadic Alzheimer's disease: an FDG-PET study. Neurology 1989;39(Suppl 1):167.

36. Holman BL, Johnson KA, Gerada B, Carvalho PA, Satlin A. The scintigraphic appearance of Alzheimer's disease: a prospective study using technetium-99m-HMPAO SPECT. J Nucl Med 1992; 33:181–185.

37. Holman BL, Nagel JS, Johnson KA, Hill TC. Imaging dementia with SPECT. Ann NY Acad Sci 1991;620:165–174.

38. Horwitz B, Grady CL, Schlageter NL, Duara R, Rapoport SI. Intercorrelations of regional cerebral glucose metabolic rates in Alzheimer's disease. Brain Res 1987;407:294–306.

39. Hounsfield GN. Computerized transverse axial scanning (tomography), part I: description of system. Br J Radiol 1973;46:1016–1022.

40. Jellinger K. Neuropathological aspects of dementias resulting from abnormal blood and cerebrospinal fluid dynamics. Acta Neurol Belg 1976;76:83–102.

41. Kalaria RN, Harik SI. Reduced glucose transporter at the blood–brain barrier and in cerebral cortex in Alzheimer disease. J Neurochem 1989;53:1083–1088.

42. Kaye JA, DeCarli C, Luxenberg JS, Rapoport SI. The significance of age-related enlargement of the cerebral ventricles in healthy men and women measured by quantitative computed X-ray tomography. J Am Geriatr Soc 1992;40:225–231.

43. Killen AR, Oster G, Colditz GA. An assessment of the role of 123I-N-isopropyl-p-iodoamphetamine with single-photon emission computed tomography in the diagnosis of stroke and Alzheimer's disease. Nucl Med Commun 1989;10:271–284.

44. Kozachuk WE, DeCarli C, Schapiro MB, Wagner EE, Rapoport SI, Horwitz B. White matter hyperintensities in dementia of Alzheimer's type and in healthy subjects without cerebrovascular risk factors. A magnetic resonance imaging study. Arch Neurol 1990;47:1306–1310.

45. Kumar A, Schapiro MB, Grady C, et al. High-resolution PET studies in Alzheimer's disease. Neuropsychopharmacology 1991;4:35–46.

46. Kuwabara Y, Ichiya Y, Otsuka M, Masuda K, Ichimiya A, Fujishima M. Cerebrovascular responsiveness to hypercapnia in Alzheimer's dementia and vascular dementia of the Binswanger type. Stroke 1992;23:594–598.

47. Kwong KK, Belliveau JW, Chesler DA, et al. Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proc Natl Acad Sci USA 1992;89:5675–5679.

48. Lechner H, Bertha G. Multiinfarct dementia. J Neural Transm [Suppl.] 1991;33:49–52.

49. Luria AR. Higher cortical functions in man. New York: Basic Books, 1966;513.

50. Luxenberg JS, Friedland RP, Rapoport SI. Quantitative X-ray computed tomography (CT) in dementia of the Alzheimer type (DAT). Can J Neurol Sci 1986;13:570–572.

51. Luxenberg JS, Haxby JV, Creasey H, Sundaram M, Rapoport SI. Rate of ventricular enlargement in dementia of the Alzheimer type correlates with rate of neuropsychological deterioration. Neurology 1987;37:1135–1140.

52. Mash DC, Flynn DD, Potter LT. Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science 1985;31:1115–1117.

53. Mayeux R, Stern Y, Spanton S. Heterogeneity in dementia of the Alzheimer type: evidence of subgroups. Neurology 1985;35:453–461.

54. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer's disease. Neurology 1984;34:939–944.

55. Miller BL, Moats RA, Shonk T, Ernst T, Woolley S, Ross BD. Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology 1993;187:433–437.

56. Mueller-Gaertner HW, Mayberg HS, Tune L, et al. Mu opiate receptor binding in amygdala in Alzheimer's disease: in vivo quantification by 11C carfentanil and PET. J Cereb Blood Flow Metab 1991;11(Suppl 2):S20.

57. Murphy DGM, Bottomley PA, Salerno J, et al. An in vivo study of glucose and phosphorus metabolism in Alzheimer's disease using magnetic resonance spectroscopy and PET. Arch Gen Psychiatry 1993;50:341–349.

58. Murphy DGM, DeCarli C, Daly E, et al. Volumetric magnetic resonance imaging in men with dementia of the Alzheimer type: correlations with disease severity. Biol Psychiatry 1993;34:612–621.

59. Nordberg A, Lilja A, Lundqvist H, et al. Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography. Neurobiol Aging 1992;13:747–758.

60. Parani D, Di Piero V, Vallar G, et al. Technetium-99m HM-PAO-SPECT study of regional cerebral perfusion in early Alzheimer's disease. J Nucl Med 1988;29:1507–1514.

61. Pettegrew JW, Moossy J, Withers G, McKeag D, Panchalingam K. 31P nuclear magnetic resonance study of the brain in Alzheimer's disease. J Neuropathol Exp Neurol 1988;47:235–248.

62. Pietrini P, Azari NP, Grady CL, et al. Pattern of cerebral metabolic interactions in a subject with isolated amnesia at risk for Alzheimer's disease: a longitudinal evaluation. Dementia 1993;4:94–101.

63. Raichle ME, Grubb RL Jr, Gado MH, Eichling JO, Ter-Pogossian MM. Correlation between regional cerebral blood flow and oxidative metabolism. Arch Neurol 1976;33:523–526.

64. Rapoport SI. Brain evolution and Alzheimer's disease. Rev Neurol (Paris) 1988;144:79–90.

65. Rapoport SI. Integrated phylogeny of the primate brain, with special reference to humans and their diseases. Brain Res Rev 1990; 15:267–294.

66. Rapoport SI. Positron emission tomography in Alzheimer's disease in relation to disease pathogenesis: a critical review. Cerebrovasc Brain Metab Rev 1991;3:297–335.

67. Rapoport SI, Grady CL. Parametric in vivo brain imaging during activation to examine pathological mechanisms of functional failure in Alzheimer disease. Int J Neurosci 1993;70:39–56.

68. Reed BR, Jagust WJ, Seab JP, Ober BA. Memory and regional cerebral blood flow in mildly symptomatic Alzheimer's disease. Neurology 1989;39:1537–1539.

69. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980;7:486–488.

70. Schapiro MB, Haxby JV, Grady CL, et al. Decline in cerebral glucose utilization and cognitive function with aging in Down's syndrome. J Neurol Neurosurg Psychiatry 1987;50:766–774.

71. Schlageter NL, Carson RE, Rapoport SI. Examination of blood–brain barrier permeability in dementia of the Alzheimer type with [68-Ga]EDTA and positron emission tomography. J Cereb Blood Flow Metab 1987;71:1–8.

72. Shulman RG, Blamire AM, Rothman DL, McCarthy G. Nuclear magnetic resonance imaging and spectroscopy of human brain function. Proc Natl Acad Sci USA 1993;90:3127–3133.

73. Tune L, Brandt J, Frost JJ, et al. Physostigmine in Alzheimer's disease: effects on cognitive functioning, cerebral glucose metabolism analyzed by positron emission tomography and cerebral blood flow analyzed by single photon emission tomography. Acta Psychiatr Scand [Suppl] 1991;366:61–65.

74. Tyrrell PJ, Sawle GV, Ibanez V, Gloomfield PM, Leenders KL, Frackowiak RS, Rossor MN. Clinical and positron emission tomography studies in the "extrapyramidal syndrome" of dementia of the Alzheimer type. Arch Neurol 1990;47:1318–1323.

75. Weinberger DR, Jones D, Reba RC, et al. A comparison of FDG PET and IQNB SPECT in normal subjects and in patients with dementia. J Neuropsychiatry Clin Neurosci 1992;4:239–248.

76. Weinstein HC, Haan J, van Royen EO, et al. SPECT in the diagnosis of Alzheimer's disease and multi-infarct-dementia. Clin Neurol Neurosurg 1991;93:39–43.

77. Yao H, Sadoshima S, Ibayashi S, Kuwabara Y, Ichiya Y, Fujishima M. Leukoaraiosis and dementia in hypertensive patients. Stroke 1992;23:1673–1677.

78. Zeeberg BR, Kim H-J, Reba RC. Pharmacokinetic simulations of SPECT quantitation of the M2 muscarinic neuroreceptor subtype in disease states using radioiodinated (R,R)-4IQNB. Life Sci 1992; 51:661–670.